About 30 results found for searched term "ADC Linker" (0.174 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9872 | BS3 (bis(sulfosuccinimidyl)suberate) | Drug-Linker Conjugates for ADC |
| BS3 Crosslinker | ||
| BS3 (bis(sulfosuccinimidyl)suberate) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M9879 | Sulfo-SMCC sodium | Drug-Linker Conjugates for ADC |
| Sulfo-SMCC sodium is a commonly used hetero-bifunctional, noncleavable ADC crosslinker bearing N-hydroxysuccinimide (NHS) ester and maleimide groups to react with primary amines and sulfhydryl groups, respectively. | ||
| M10199 | DSS Crosslinker (Disuccinimidyl suberate) | Drug-Linker Conjugates for ADC |
| Disuccinimidyl suberate | ||
| DSS Crosslinker (Disuccinimidyl suberate) is a non-cleavable, cell membrane permeable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M10396 | Deruxtecan | Drug-Linker Conjugates for ADC |
| Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | ||
| M10402 | MC-GGFG-DX8951 | Drug-Linker Conjugates for ADC |
| Trastuzumab Impurity 1 | ||
| MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker. | ||
| M10405 | Fmoc-Val-Cit-PAB-MMAE | Drug-Linker Conjugates for ADC |
| Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADCs that consists of a ADC linker (Fmoc-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). | ||
| M10406 | N3-PEG3-vc-PAB-MMAE | Drug-Linker Conjugates for ADC |
| N3-PEG3-vc-PAB-MMAE is a synthesized drug-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. | ||
| M10411 | Fmoc-Val-Cit-PAB-PNP | ADC Linker |
| Fmoc-Val-Cit-PAB-PNP is a cleavable peptide ADC linker which used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M10412 | Val-cit-PAB-OH | ADC Linker |
| Val-cit-PAB-OH is a cathepsin cleavable ADC peptide linker for making MC-Val-Cit-PAB, which is also known as MC-Val-Cit-PAB-OH. | ||
| M10413 | Boc-Val-Cit-PAB | ADC Linker |
| Boc-Val-Cit-PABA | ||
| Boc-Val-Cit-PAB is a cleavable ADC linker used in making antibody-drug conjugates (ADCs). | ||
| M10414 | Fmoc-3VVD-OH | ADC Linker |
| Fmoc-3VVD-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M13342 | DSG Crosslinker | ADC Linker |
| DSG Crosslinker is a cleavable ADC linker that can be used to synthesize antibody-conjugated drugs (ADCs). | ||
| M13453 | DBCO-NHS ester | ADC Linker |
| DBCO-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M13454 | DSP Crosslinker | ADC Linker |
| DSP Crosslinker is a cleavable ADC linker, used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M13455 | Fmoc-Phe-Lys(Boc)-PAB-PNP TFA | ADC Linker |
| Fmoc-Phe-Lys(Boc)-PAB-PNP TFA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | ||
| M24661 | Sofituzumab vedotin | Drug-Linker Conjugates for ADC |
| DMUC5754A | ||
| Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer. | ||
| M24697 | Labetuzumab govitecan | Drug-Linker Conjugates for ADC |
| IMMU 130 hMN-14-SN-38 | ||
| Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer. | ||
| M24744 | Laprituximab emtansine | EGFR/HER2 |
| IMGN-289; J2898A-SMCC-DM1 | ||
| Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research. | ||
| M24756 | Ladiratuzumab vedotin | Drug-Linker Conjugates for ADC |
| SGN-LIV1A | ||
| Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer. | ||
| M24824 | Sirtratumab vedotin | Drug-Linker Conjugates for ADC |
| AGS15E; ASG-15ME; 1vcMMAE | ||
| Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M24847 | Iladatuzumab vedotin | Drug-Linker Conjugates for ADC |
| DCDS-0780A | ||
| Iladatuzumab vedotin (DCDS-0780A) is an antibody-drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody conjugated to MMAE via a protease labile linker. | ||
| M24941 | Disitamab vedotin | Drug-Linker Conjugates for ADC |
| RC48 | ||
| Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. | ||
| M25010 | Patritumab deruxtecan | Drug-Linker Conjugates for ADC |
| HER3-DXd; U3-1287; U3-1402 | ||
| Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. | ||
| M25072 | Mipasetamab uzoptirine | TAM Receptor |
| ADCT-601 | ||
| Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers. | ||
| M25138 | Pivekimab sunirine | Drug-Linker Conjugates for ADC |
| IMGN 632; PVEK | ||
| Pivekimab sunirine (IMGN 632) is an antibody-drug conjugate (ADC) targeting CD123. Pivekimab sunirine comprises a high-affinity CD123 antibody, cleavable linker, and an indolinobenzodiazepine pseudodimer (IGN) payload. Pivekimab sunirine can be used for research of hematological malignancies. | ||
| M28205 | SGD-1910 | Drug-Linker Conjugates for ADC |
| SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala. | ||
| M28337 | Vc-MMAD | Microtubule |
| Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC. | ||
| M28498 | Sulfo-PDBA-DM4 | Drug-Linker Conjugates for ADC |
| Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. | ||
| M28881 | Mc-VC-PAB-SN38 | Drug-Linker Conjugates for ADC |
| Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
